Search
Ionis Pharmaceuticals Inc
IONSAdd to Watchlist
54.810USD
+0.320+0.59%
Close 08-03 16:00（ET）Quotes delayed by 15 min
9.09BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-08-03The current earnings forecast score of Ionis Pharmaceuticals Inc is 8.22, ranking 153 out of 384 in the Biotechnology & Medical Research industry. The average price target is 87.00, with a high of 110.00 and a low of 46.00.
Analyst Rating
Based on
25
analysts
Buy
Current Rating
87.829
Target Price
+69.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Ionis Pharmaceuticals Inc
IONS
25
Beigene Ltd
ONC
28
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ionis Pharmaceuticals Inc's expected revenue for the next quarter?
Ionis Pharmaceuticals Inc's expected revenue is 181.64M.
What is Ionis Pharmaceuticals Inc's price target?
Analysts forecast that Ionis Pharmaceuticals Inc's price target is USD 87.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 46.00.
How have Ionis Pharmaceuticals IncIONS's recent earnings per share performed?
The market expectation was USD -0.69, while Ionis Pharmaceuticals IncIONS's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -1.20.
What is the analyst rating for Ionis Pharmaceuticals Inc?
Based on the ratings of Ionis Pharmaceuticals Inc's stock from 25 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.